세계의 자가면역성 피부 질환 치료 시장 : 예측 - 질환 유형별, 치료 유형별, 투여 경로별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Autoimmune Skin Diseases Treatment Market is accounted for $10.05 billion in 2025 and is expected to reach $25.77 billion by 2032 growing at a CAGR of 14.4% during the forecast period. Autoimmune Conditions of the Skin the term "treatment" describes the medical procedures used to treat skin conditions brought on by the immune system inadvertently targeting healthy skin cells. Psoriasis, vitiligo, lupus erythematosus, scleroderma, pemphigus, and dermatitis herpetiformis are some of these ailments. The main goals of treatment are to minimise skin damage, reduce inflammation, inhibit aberrant immune responses, relieve symptoms, and avoid flare-ups. Systemic and topical corticosteroids, immune-suppressants, biologic treatments, phototherapy, and supportive skincare are common methods. Improving quality of life, decreasing complications, and delaying the progression of disease all depend on early diagnosis and individualized treatment strategies.

Market Dynamics:

Driver:

Rising prevalence of autoimmune skin conditions

Improved screening and more awareness have led to a rise in the diagnosis of conditions like vitiligo, lupus, and psoriasis. Healthcare professionals are adopting targeted treatments, immune-modulators, and sophisticated biologics as a result of this expanding patient base. To meet these patients' unmet requirements, pharmaceutical companies are increasing their research and development expenditures. Treatment adoption rates are also increased by favourable healthcare regulations and improved access to dermatological care. All things considered, the growing prevalence of autoimmune skin conditions drives steady market expansion.

Restraint:

High cost of biologic and advanced therapies

The inability of many patients to pay for these medicines restricts their access and adherence. High costs also put a strain on insurance companies and healthcare systems. This results in limited coverage and difficulties with reimbursement. Patients might choose less effective options as a result. These monetary obstacles hinder the uptake of cutting-edge treatments and limit market growth.

Opportunity:

Growth in healthcare expenditure and diagnostics

Patient outcomes are improved by increased funding, which encourages the use of cutting-edge biologics and focused treatments. More precise disease classification and earlier detection are made possible by advancements in diagnostic capabilities. Timely intervention by early and accurate diagnosis slows the progression and complications of disease. Increased access to treatment in both urban and rural areas is made possible by growing healthcare infrastructure. These elements work together to increase demand and grow the market for treatments for autoimmune skin conditions.

Threat:

Safety concerns and adverse effects

The danger of serious side effects, like infections or organ damage, is present with many treatments. These health hazards may cause patients to avoid or stop receiving therapy. Additionally, doctors can be reluctant to recommend particular medications if their safety profiles are weak. Patient compliance and market acceptance are lowered as a result. Therefore, the adoption of beneficial medicines is slowed by the fear of danger.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Autoimmune Skin Diseases Treatment Market by disrupting supply chains, delaying clinical trials, and limiting patient access to healthcare facilities. Lockdowns and healthcare resource reallocation led to postponed diagnoses and treatment schedules, impacting patient outcomes. Telemedicine adoption accelerated, enabling remote consultations and prescription management. Pharmaceutical companies faced challenges in production and distribution but also saw increased focus on developing advanced therapies. Post-pandemic recovery is driven by resumed elective treatments, improved healthcare accessibility, and growing awareness of autoimmune skin disease management.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period by offering targeted therapies that address the underlying immune system dysfunction. These treatments provide higher efficacy and longer remission periods compared to conventional drugs, boosting patient demand. Advancements in biologic formulations and delivery methods enhance safety and convenience, increasing adoption rates. Growing approvals of novel biologics for conditions like psoriasis and atopic dermatitis expand the treatment portfolio. Rising awareness among healthcare providers and patients further accelerates market growth for biologics.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by offering patients convenient access to therapies and monitoring in their own homes, reducing the need for frequent hospital visits. It supports better treatment adherence through self-administration options and remote guidance from healthcare providers. Advancements in portable devices and telemedicine enhance the feasibility of home-based care. Overall, homecare settings improve patient outcomes while lowering healthcare costs, driving market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share is driven by high disease prevalence, well developed healthcare infrastructure, and robust research funding. Advanced pharmaceuticals particularly biologics and JAK inhibitors plus favourable reimbursement policies support rapid adoption of novel therapies. Regulatory agencies facilitate accelerated drug approvals and bio similar entry. Cutting edge diagnostic and precision medicine technologies, including AI assisted imaging and multiplex assays, are increasingly used, with strategic collaborations between biotech firms and academic institutions powering continuous innovation in therapies for conditions such as psoriasis, eczema and lupus.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR is fuelled by rising autoimmune disease incidence tied to aging populations, urbanization and evolving lifestyles. Investments in healthcare infrastructure, expansion of public insurance coverage and generics production bolster treatment access. Emerging technologies include AI enabled teledermatology, mobile diagnostics, and hyper spectral imaging and nanostructure topical therapeutics under development. Regional innovation trends emphasize cost-effective, localized solutions-often in collaboration with global pharma supporting scalable deployment of diagnostics and precision therapies tailored to regional needs and healthcare disparities.

Key players in the market

Some of the key players in Autoimmune Skin Diseases Treatment Market include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, Biogen Inc., Sanofi S.A., UCB S.A., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., AstraZeneca plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Horizon Therapeutics plc and Incyte Corporation.

Key Developments:

In April 2025, Amgen announced a $900 million expansion of its New Albany, Ohio biomanufacturing facility. The investment aims to boost production capacity for both pipeline and commercial biologics, potentially supporting treatments in autoimmune dermatology. This expansion strengthens Amgen's manufacturing network to meet growing global demand for innovative therapies.

In January 2025, AbbVie completed its ~$200 million acquisition of Nimble Therapeutics, gaining its lead oral peptide IL 23 receptor inhibitor for psoriasis and inflammatory bowel disease, along with Nimble's proprietary peptide drug discovery platform to advance targeted autoimmune disease therapies.

In June 2023, Eli Lilly agreed to acquire Dice Therapeutics for $2.4 billion in cash (approximately $48 per share). The deal focuses on Dice's innovative oral IL 17 inhibitors, notably DC 806 in phase II psoriasis trials, along with other pipeline assets aimed at advancing treatments for autoimmune and inflammatory skin diseases.

Disease Types Covered:

• Psoriasis
• Atopic Dermatitis
• Vitiligo
• Pemphigus Vulgaris
• Lupus Erythematosus
• Other Disease Types

Therapy Types Covered:

• Biologics
• Corticosteroids
• Immunosuppressants
• Small Molecule Drugs
• Other Therapy Types

Route of Administrations Covered:

• Oral
• Injectable
• Topical

End Users Covered:

• Hospitals
• Specialty Clinics
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Autoimmune Skin Diseases Treatment Market, By Disease Type

• 5.1 Introduction
• 5.2 Psoriasis
• 5.3 Atopic Dermatitis
• 5.4 Vitiligo
• 5.5 Pemphigus Vulgaris
• 5.6 Lupus Erythematosus
• 5.7 Other Disease Types

6 Global Autoimmune Skin Diseases Treatment Market, By Therapy Type

• 6.1 Introduction
• 6.2 Biologics
• 6.3 Corticosteroids
• 6.4 Immunosuppressants
• 6.5 Small Molecule Drugs
• 6.6 Other Therapy Types

7 Global Autoimmune Skin Diseases Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Injectable
• 7.4 Topical

8 Global Autoimmune Skin Diseases Treatment Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Specialty Clinics
• 8.4 Homecare Settings
• 8.5 Other End Users

9 Global Autoimmune Skin Diseases Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 AbbVie Inc.
• 11.2 Amgen Inc.
• 11.3 Eli Lilly and Company
• 11.4 Johnson & Johnson Services, Inc.
• 11.5 Novartis AG
• 11.6 Pfizer Inc.
• 11.7 Bristol Myers Squibb Company
• 11.8 Biogen Inc.
• 11.9 Sanofi S.A.
• 11.10 UCB S.A.
• 11.11 GlaxoSmithKline plc
• 11.12 Regeneron Pharmaceuticals, Inc.
• 11.13 AstraZeneca plc
• 11.14 Merck & Co., Inc.
• 11.15 Takeda Pharmaceutical Company Limited
• 11.16 Roche Holding AG
• 11.17 Horizon Therapeutics plc
• 11.18 Incyte Corporation